News

Agathos was pleased to welcome Mark in January 2022 as the fifth member of its growing team.  Joining a small company with ambitious goals required him to come up to speed quickly.  “I am excited to be a part of Agathos and create ethically-developed products and services for genetic medicine and biotechnology,” said Voigt.  “It has been an intense first few months during which I have immersed myself in the science and strategy of the company.  I’m committed to working with the talented founders and team members to create innovative solutions that will positively impact patients, researchers, and healthcare providers.”

Voigt was Director, General and Vascular Surgery at St. Cloud Hospital – CentraCare where he was responsible for physician recruitment and contracting as well as developing new service lines for the health system.  Prior to that, he was Key Account Manager at R&D Systems where he worked with scientists, lab managers, and directors to identify products and services to meet their experimental needs for drug discovery, biomarker screening, and translational research.

“Each team member at Agathos must work across functions in a fast-paced environment.  Mark has already made significant contributions in a variety of areas, from lab management and procurement to evaluating technology and market opportunities,” said James Brown, CEO of Agathos.  “His diverse background in biotechnology sales, product development, and healthcare management brings a set of skills that are important for our success.  Mark’s energy and enthusiasm is infectious and has a positive impact on everyone.”

The addition of Mark’s role, the recent addition of laboratory and office space, and the recruiting of new scientist and research associate positions are part of the company’s plan for continued growth in 2022.  “The founders of Agathos are dedicated to developing new, ethically-developed tools and therapies for genetic medicine and look forward to growing the company to achieve these goals,” added Brown.